Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) were recognized to cause endocrine adverse reactions (EARs). However, combination therapy-associated EARs are still ...

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in ...

Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive ...

Chen, D. and Li, L. (2025) Huge Pelvic GIST Got Good Control after Resistance to Tyrosine Kinase Inhibitors by SIB-IMRT: A ...

SciClone will develop and distribute Tasfygo in greater China but Eisai will retain worldwide rights outside the region.

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...